Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
RYTHMOL is an oral small-molecule antiarrhythmic agent approved in 1989 for the treatment of cardiac arrhythmias. The drug is a Class IC antiarrhythmic that works by slowing conduction velocity in cardiac tissue. It is indicated for patients with ventricular arrhythmias requiring suppression.
As LOE approaches, the brand team is likely consolidating and focusing on mature-market management with minimal growth investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
RYTHMOL currently shows zero linked job postings, reflecting its mature, declining lifecycle status. Career opportunities on this brand are limited and primarily focused on defending market share and managing the transition to generic competition rather than growth initiatives.
Worked on RYTHMOL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.